Cardiff Oncology, Inc.
CRDFHealthcare|Biotechnology|US
$0.80
+0.04 (+5.30%)
DCF Value
$0.03
Tangible Book / Share
$0.39
Cash / Share
$0.50
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05383196 Onvansertib + Paclitaxel In TNBC | Breast Cancer, Invasive Breast Cancer | P1P2 | Active | 50 | Open-label | Onvansertib, Paclitaxel |
| NCT06736717 Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer | Pancreatic Cancer | P1P2 | Active | 16 | Open-label | Onvansertib, NALIRIFOX |
| NCT06106308 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | Metastatic Colorectal Cancer, CRC | P2 | Active | 110 | RCT, Open-label | Onvansertib, FOLFIRI, Bevacizumab, FOLFOX |
| NCT05450965 Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | Small-cell Lung Cancer, Small Cell Lung Carcinoma | P2 | Recruiting | 37 | Open-label | Onvansertib |
| NCT04005690 Targeted Pathway Inhibition in Patients With Pancreatic Cancer | Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Early P1 | Recruiting | 90 | Open-label | Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib, Tremelimumab |
| NCT05775068 ARtificial Intelligence for Gross Tumour vOlume Segmentation | Lung Cancer | Active | 2,000 | — | — | |
| NCT03303339 Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | P1P2 | Completed | 72 | Open-label | Onvansertib, Cytarabine, Decitabine |
| NCT03414034 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer | P2 | Completed | 72 | Open-label | Onvansertib, Abiraterone, Prednisone |
| NCT03829410 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation | Metastatic Colorectal Cancer, KRAS Gene Mutation | P1P2 | Completed | 68 | Open-label | Onvansertib, Bevacizumab, FOLFIRI |
| NCT04752696 Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | P2 | Terminated | 41 | Open-label | Onvansertib, Nanoliposomal irinotecan, Leucovorin, Fluorouracil |
| NCT05593328 Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | Colorectal Cancer, Metastatic Colorectal Cancer | P2 | Completed | 23 | RCT, Open-label | Onvansertib, FOLFIRI, Bevacizumab |
| NCT02186236 Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients | Lung Cancer, Colorectal Cancer | Completed | 84 | — | — | |
| NCT04446793 Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | Metastatic Colorectal Cancer, KRAS Gene Mutation | NO_LONGER_AVAILABLE | — | — | Onvansertib, Bevacizumab, FOLFIRI | |
| NCT03564457 20K Distributed Learning Challenge | Non Small Cell Lung Cancer | Completed | 20,000 | — | — |